Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

por Nieto, Yago, Valdez, Benigno C, Pingali, Sai R, Bassett, Roland, Delgado, Ruby, Nguyen, John, Shah, Nina, Popat, Uday, Jones, Roy B, Andersson, Borje S, Gulbis, Alison, Ahmed, Sairah, Bashir, Qaiser, Parmar, Simrit, Patel, Krina, Myers, Alan, Rondon, Gabriela, Orlowski, Robert Z, Champlin, Richard, Qazilbash, Muzaffar
Publicado 2017

Decrease post-transplant relapse using donor-derived expanded NK-cells

por Ciurea, Stefan O., Kongtim, Piyanuch, Soebbing, Doris, Trikha, Prashant, Behbehani, Gregory, Rondon, Gabriela, Olson, Amanda, Bashir, Qaiser, Gulbis, Alison M., Indreshpal, Kaur, Rezvani, Katayoun, Shpall, Elizabeth J., Bassett, Roland, Cao, Kai, Martin, Andrew St, Devine, Steven, Horowitz, Mary, Pasquini, Marcelo, Lee, Dean A., Champlin, Richard E.
Publicado 2021

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation

por Konopleva, Marina, Benton, Christopher B., Thall, Peter F., Zeng, Zhihong, Shpall, Elizabeth, Ciurea, Stefan, Kebriaei, Partow, Alousi, Amin, Popat, Uday, Anderlini, Paolo, Nieto, Yago, Parmar, Simrit, Qiao, Wei, Chen, Julianne, Rondon, Gabriela, McMullin, Becky, Wang, Rui-Yu, Lu, Hongbo, Schober, Wendy, Woodworth, Glenda, Gulbis, Alison, Cool, Rita, Andreeff, Michael, Champlin, Richard
Publicado 2015

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

por Andersson, Borje S., Thall, Peter F., Ma, Junsheng, Valdez, Benigno C., Bassett, Roland, Chen, Julianne, Ahmed, Sairah, Alousi, Amin, Bashir, Qaiser, Ciurea, Stefan, Gulbis, Alison, Cool, Rita, Kawedia, Jitesh, Hosing, Chitra, Kebriaei, Partow, Kornblau, Steve, Myers, Alan, Oran, Betul, Rezvani, Katayoun, Shah, Nina, Shpall, Elizabeth, Parmar, Simrit, Popat, Uday R., Nieto, Yago, Champlin, Richard E.
Publicado 2022

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

por Andersson, Borje S., Thall, Peter F., Valdez, Benigno C., Milton, Denái R., Al-Atrash, Gheath, Chen, Julianne, Gulbis, Alison, Chu, Diem, Martinez, Charles, Parmar, Simrit, Popat, Uday, Nieto, Yago, Kebriaei, Partow, Alousi, Amin, de Lima, Marcos, Rondon, Gabriela, Meng, Qing H., Myers, Alan, Kawedia, Jitesh, Worth, Laura L., Fernandez-Vina, Marcelo, Madden, Timothy, Shpall, Elizabeth J., Jones, Roy B., Champlin, Richard E.
Publicado 2016

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities

por Popat, Uday R., Pasvolsky, Oren, Bassett Jr., Roland, Mehta, Rohtesh S., Olson, Amanda, Chen, Julianne, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Gulbis, Alison M., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Oran, Betul, Saini, Neeraj, Shigle, Terri Lynn, Srour, Samer A., Ramdial, Jeremy L., Rezvani, Katayoun, Qazilbash, Muzaffar H., Andersson, Borje S., Champlin, Richard E., Shpall, Elizabeth J.
Publicado 2023

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune...

por Saberian, Chantal, Abdel-Wahab, Noha, Abudayyeh, Ala, Rafei, Hind, Joseph, Jacinth, Rondon, Gabriela, Whited, Laura, Gruschkus, Stephen, Fa'ak, Faisal, Daher, May, Knape, Cristina, Safa, Houssein, Shoukier, Mahran, Suarez-Almazor, Maria E, Marcotulli, Megan, Ludford, Kaysia, Gulbis, Alison M, Konopleva, Marina, Ohanian, Maro, Ravandi, Farhad, Garcia-Manero, Guillermo, Oran, Betul, Popat, Uday R, Mehta, Rotesh, Alousi, Amin M, Daver, Naval, Champlin, Richard, Diab, Adi, Al-Atrash, Gheath
Publicado 2021

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES

por Popat, Uday R., Lontos, Konstantinos, Bassett, Roland, Kawedia, Jitesh, Valdez, Ben C., Gulbis, Alison, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Mehta, Rohtesh S., Nieto, Yago, Oran, Betul, Olson, Amanda, Qazilbash, Muzaffar H., Ramdial, Jeremy L., Saini, Neeraj, Srour, Samer A., Kadia, Tapan, Daver, Naval, Short, Nicholas, Rezvani, Katayoun, Shpall, Elizabeth J., Champlin, Richard E., Andersson, Borje S.
Publicado 2023

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

por Nieto, Yago, Gruschkus, Stephen, Valdez, Benigno C., Jones, Roy B., Anderlini, Paolo, Hosing, Chitra, Popat, Uday, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Saini, Neeraj, Srour, Samer, Rezvani, Katayoun, Ramdial, Jeremy, Barnett, Melissa, Gulbis, Alison, Shigle, Terri Lynn, Ahmed, Sairah, Iyer, Swaminathan, Lee, Hun, Nair, Ranjit, Parmar, Simrit, Steiner, Raphael, Dabaja, Bouthaina, Pinnix, Chelsea, Gunther, Jillian, Cuglievan, Branko, Mahadeo, Kris, Khazal, Sajad, Chuang, Hubert, Champlin, Richard, Shpall, Elizabeth J., Andersson, Borje S.
Publicado 2021

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

por Mahadeo, Kris M., Khazal, Sajad J., Abdel-Azim, Hisham, Fitzgerald, Julie C., Taraseviciute, Agne, Bollard, Catherine M., Tewari, Priti, Duncan, Christine, Traube, Chani, McCall, David, Steiner, Marie E., Cheifetz, Ira M., Lehmann, Leslie E., Mejia, Rodrigo, Slopis, John M., Bajwa, Rajinder, Kebriaei, Partow, Martin, Paul L., Moffet, Jerelyn, McArthur, Jennifer, Petropoulos, Demetrios, O’Hanlon Curry, Joan, Featherston, Sarah, Foglesong, Jessica, Shoberu, Basirat, Gulbis, Alison, Mireles, Maria E., Hafemeister, Lisa, Nguyen, Cathy, Kapoor, Neena, Rezvani, Katayoun, Neelapu, Sattva S., Shpall, Elizabeth J.
Publicado 2018